IP Verse

Alt-803 In Combination With Anti-Cd38 Antibody For Cancer Therapies - EP3601363

The patent EP3601363 was granted to Altor Bioscience on Jun 15, 2022. The application was originally filed on Mar 30, 2018 under application number EP18776459A. The patent is currently recorded with a legal status of "Opposition Rejected".

EP3601363

ALTOR BIOSCIENCE
Application Number
EP18776459A
Filing Date
Mar 30, 2018
Status
Opposition Rejected
Oct 11, 2024
Publication Date
Jun 15, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

CYTUNE PHARMAMar 15, 2023MAIWALDADMISSIBLE

Patent Citations (24) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS20080151980
DESCRIPTIONEP0404097
DESCRIPTIONUS1975
DESCRIPTIONUS2009148449
DESCRIPTIONUS2014205560
DESCRIPTIONUS222
DESCRIPTIONUS4816567
DESCRIPTIONUS5116964
DESCRIPTIONUS5541087
DESCRIPTIONUS5620939
DESCRIPTIONUS5641870
DESCRIPTIONUS7213961
DESCRIPTIONUS8507
DESCRIPTIONWO2005046449
DESCRIPTIONWO2016004060
DESCRIPTIONWO9311161
DESCRIPTIONWO9404689
DESCRIPTIONWO9429350
DESCRIPTIONWO9632478
DESCRIPTIONWO9734631
EXAMINATIONWO2016004060
INTERNATIONAL-SEARCH-REPORTUS2009148449
INTERNATIONAL-SEARCH-REPORTUS2014205560
OPPOSITIONWO2016004060

Non-Patent Literature (NPL) Citations (11) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
OPPOSITION- WEI et al., "The Sushi Domain of Soluble IL -15 Receptor a Is Essential for Binding IL -15 and Inhibiting Inflammatory and Allogenic Responses In Vitro and In Vivo", J Immunol, (20010000), vol. 167, pages 277 - 282, XP002394329
OPPOSITION- OCHOA et al., "Antibody-dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells", Immunology and Cell Biology, (20170000), vol. 95, doi:10.1038/icb.2017.6, pages 347 - 355, XP055510714
OPPOSITION- Tilman Schlothauer et al, "Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions", PROTEIN ENGINEERING, DESIGN AND SELECTION, OXFORD JOURNAL, LONDON, GB, GB , (20161001), vol. 29, no. 10, doi:10.1093/protein/gzw040, ISSN 1741-0126, pages 457 - 466, XP055414310
OPPOSITION- VAN DE DONK et al., "Monoclonal antibodies targeting CD 38 in hematological malignancies and beyond", Immunological Reviews, (20160000), vol. 270, doi:10.1111/imr.12389, pages 95 - 112, XP071456198
OPPOSITION- Tatiana A. Karakasheva et al., "CD38-Expressing Myeloid-Derived Suppressor Cells Promote Tumor Growth in a Murine Model of Esophageal Cancer", Cancer Res, (20151001), vol. 75, doi:10.1158/0008-5472.CAN-14-3639, XP055496986
OPPOSITION- ROSARIO et al., "The IL -15-Based ALT-803 Complex Enhances FcyRllla- Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas", Clin Cancer Res, (20160201), vol. 22, no. 3, doi:10.1158/1078-0432.CCR-15-1419, XP055499003
OPPOSITION- Jakub Krejcik et al., "Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma", Blood, (20160721), vol. 128, doi:10.1182/blood-2015-12-687749, XP086685970
OPPOSITION- SANCHEZ et al., "Daratumumab: a first-in-class CD 38 monoclonal antibody for the treatment of multiple myeloma", Journal of Hematology & Oncology, (20160000), vol. 9, doi:10.1186/s13045-016-0283-0, page 51, XP055914138
OPPOSITION- Liu Hongyan, Saxena Abhishek, Sidhu Sachdev S., Wu Donghui, "Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds", Frontiers in Immunology, (20170101), vol. 8, doi:10.3389/fimmu.2017.00038, pages 1 - 15, XP093037588
SEARCH[ ] - MARIA CARMEN OCHOA ET AL, "Antibody-dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells", IMMUNOLOGY AND CELL BIOLOGY, AU, (20170221), vol. 95, no. 4, doi:10.1038/icb.2017.6, ISSN 0818-9641, pages 347 - 355, XP055510714 [ ] * the whole document *
SEARCH- PETER S. KIM ET AL, "IL-15 superagonist/IL-15R[alpha]Sushi-Fc fusion complex (IL-15SA/IL-15R[alpha]Su-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas", ONCOTARGET, United States, (20160329), vol. 7, no. 13, doi:10.18632/oncotarget.7470, ISSN 1949-2553, pages 16130 - 16145, XP055403855 [I] 1-4,6-12,15 * the whole document *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents